In conclusion, for patients with NSCLC accompanied by cachexia and elevated plasma IL‐6 levels, the addition of tocilizumab to standard anticancer treatments appears to mitigate the effects of cancer cachexia and extend survival, while also enhancing tolerance to conventional oncologic therapies. Here, IL6 is linked to non-small cell lung carcinoma.